Glomerular and Tubular Functions in Children and Adults with Transfusion-Dependent Thalassemia

Agageldi Annayev, Zeynep Karakaş, Serap Karaman, Altan Yalçıner, Alev Yılmaz, Sevinç Emre, Agageldi Annayev, Zeynep Karakaş, Serap Karaman, Altan Yalçıner, Alev Yılmaz, Sevinç Emre

Abstract

This study aimed at assessing renal functions in patients with transfusion-dependent thalassemia (TDT). Fifty patients and 30 controls were enrolled in this prospective study. Serum levels of electrolytes and albumin were measured by a spectrophotometer. Serum levels of cystatin-C and urinary levels of β2-microglobulin were measured by nephelometric method. Thirty-eight patients were receiving deferasirox and 8 were on deferiprone. Serum electrolytes and albumin levels of the patients were found to be within normal ranges. Urinary β2-microglobulin and serum cystatin-C levels were significantly higher in patients than controls. They did not significantly differ between the subgroup of patients on deferiprone and the control group, whereas they were found to be higher in patients using deferasirox compared to controls. Urinary β2-microglobulin levels significantly increased in patients who were receiving high-dose deferasirox compared to those who were receiving a daily dose of 15-20 mg/kg or controls. Subclinical renal injury may be present in TDT patients.

Keywords: Glomerulopathy; Thalassemia; Tubulopathy; β2-Microglobulin Cystatin..

Conflict of interest statement

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

Figures

Figure 1. Correlations between pretransfusion hemoglobin and…
Figure 1. Correlations between pretransfusion hemoglobin and urinary β2-microglobulin and serum cystatin-C. Uβ2MG: Urinary β2-microglobulin, SCys-C: serum cystatin-C, Hb: hemoglobin.
Figure 2. Correlations between heart T2* and…
Figure 2. Correlations between heart T2* and Uβ2MG and SCys-C. Uβ2MG: Urinary β2-microglobulin, SCys-C: serum cystatin-C, MRI: magnetic resonance imaging.

References

    1. Steinberg MH, Higgs DR, Weatherall DJ. Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management. 2nd ed. Cambridge, Cambridge University Press, 2009.
    1. Musallam KM, Capellini MD, Taher AT. Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol. 2013;20:187–192.
    1. Mohkam M, Shamsian BS, Gharib A, Nariman S, Arzanian MT. Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatr Nephrol. 2008;23:971–976.
    1. Aldudak B, Karabay Bayazit A, Noyan A, Ozel A, Anarat A, Sasmaz I, Kilinç Y, Gali E, Anarat R, Dikmen N. Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol. 2000;15:109–112.
    1. Jafari HM, Vahidshahi K, Kosaryan M, Karami H, Mandavi MR, Ehteshami S. Major beta-thalassemia, use of desferiexamine and renal proximal tubular damage. Bratisl Lek Listy. 2011;112:278–281.
    1. Sadeghi-Bojd S, Hashemi M, Karimi M. Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran. Singapore Med J. 2008;49:410–412.
    1. Mula-Abed WA, Al-Hashmi HS, Al-Muslahi MN. Indicators of renal glomerular and tubular functions in patients with beta-thalassaemia major: A cross sectional study at the Royal Hospital, Oman. Sultan Qaboos Univ Med J. 2011;11:69–76.
    1. Deveci B, Kurtoglu A, Kurtoglu E, Salim O, Toptas T. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia. Ann Hematol. 2016;95:375–381.
    1. Kalman S, Atay AA, Sakallioglu O, Ozgürtaş T, Gök F, Kurt I, Kürekçi AE, Ozcan O, Gökçay E. Renal tubular function in children with beta-thalassemia minor. Nephrology (Carlton) 2005;10:427–429.
    1. Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, Koren A. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol. 2008;23:1847–1851.
    1. Lai ME, Spiga A, Vacquer S, Carta MP, Corrias C, Ponticelli C. Renal function in patients with β-thalassaemia major: a long-term follow-up study. Nephrol Dial Transplant. 2012;27:3547–3551.
    1. Almadzadeh A, Jalali A, Assar S, Khalilian H, Zandian K, Pedram M. Renal tubular dysfunction in pediatric patients with beta-thalassemia major. Saudi J Kid Dis Transpl. 2011;22:497–450.
    1. Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol. 2010;123:148–152.
    1. Ali BA, Mahmoud AM. Frequency of glomerular dysfunction in children with beta thalassaemia major. Sultan Qaboos Univ Med J. 2014;14:88–94.
    1. Hamed AE, Elmelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Ital J Pediatr. 2010;30:36–39.
    1. Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, Athanasiou M. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol. 2003;25:105–109.
    1. Papassotiriou I, Margeli A, Hantzi E, Delaporta P, Sergounioti A, Goussetis E, Ladis V, Kattamis A. Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood Cells Mol Dis. 2010;44:152–155.
    1. Prasannan L, Flynn JT, Levine JE. Acute renal failure following deferoxamine overdose. Pedi¬atr Nephrol. 2003;18:283–285.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere